CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
多发性骨髓瘤患者 CAR-T 细胞治疗后 HIV-1 RNA 假阳性检出：多方法比较证实双靶点交叉反应
英文原题：False-positive HIV-1 RNA detection after CAR-T cell therapy in a multiple myeloma patient: multi-assay comparison confirms dual-target cross-reactivity.
查看英文原题
False-positive HIV-1 RNA detection after CAR-T cell therapy in a multiple myeloma patient: multi-assay comparison confirms dual-target cross-reactivity.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
采用慢病毒载体的CAR-T 细胞 疗法可能会因载体衍生序列的扩增而导致假阳性 HIV-1 RNA 结果。我们描述了一名接受 CAR-T 治疗的多发性骨髓瘤患者的病例，该患者通过两项双靶点检测检测，结果呈低拷贝 HIV-1 RNA 阳性。单靶标检测始终呈阴性。 HIV血清学测试仍然没有反应。该案例强调了检测目标设计在解释 CAR-T 治疗后 HIV RNA 结果中的重要性，并支持血清学检测和替代方法以避免误诊的重要性。
展开英文摘要原文
Chimeric antigen receptor T-cell (CAR-T) therapies, employing lentiviral vectors, may cause false-positive HIV-1 RNA results due to amplification of vector-derived sequences.
We describe a case of a patient with multiple myeloma undergoing CAR-T therapy tested with two dual-target assays testing positive at low copies for HIV-1 RNA. A single-target assay consistently tested negative. HIV serological tests remained non-reactive. This case highlights the importance of assay target design in interpreting HIV RNA results after CAR-T therapy and supports the importance of serological tests and alternative methods to avoid misdiagnosis.
论文信息
- 作者
- Brusa S、D'Angelo D、D'Ambrosio G、Furno A、Pepa RD、Leone A、Sepe C、Sorrentino R
- 单位
- Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy. Electronic address: stefano.brusa3@hotmail.it.Italy
- 文献类型
- 病例报告
- 期刊
- Diagnostic microbiology and infectious disease2026 Nov
- 原文标识
- PubMed 42492169 · DOI 10.1016/j.diagmicrobio.2026.117560